title: [A case of colon cancer with multiple liver metastases responding ot S-1 as third-line treatment following FOLFIRI and FOLFOX].
abstract: A 73-year-old man had undergone right hemicolectomy for advanced colon cancer in May 2006, and he concurrently had multiple liver metastases. After the operation, the patient was given chemotherapy with FOLFIRI. A partial response was achieved for twelve months, and then the liver tumors enlarged. Second-line chemotherapy with FOLFOX was delivered. After several months the liver tumors further enlarged and a new pulmonary lesion appeared with an increased serum CEA level. Therefore, chemotherapy with S-1 (120 mg/day) was started, with 2 weeks' administration followed by a one-week drug-free period. Several months later, the liver tumors and tumor makers decreased. S-1 is expected to be an effective agent for the treatment of advanced colon cancer with liver metastases after FOLFIRI and FOLFOX.
authors.affiliation: Dept. of Surgery, Heartlife Hospital
authors.forename: Takumi
authors.initials: T
authors.lastname: Miyahira
authors.forename: Natsuki
authors.initials: N
authors.lastname: Teruya
authors.forename: Fumiaki
authors.initials: F
authors.lastname: Matsuura
authors.forename: Shigemi
authors.initials: S
authors.lastname: Murayama
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Aka
authors.forename: Jun
authors.initials: J
authors.lastname: Teruya
authors.forename: Naoji
authors.initials: N
authors.lastname: Hanashiro
authors.forename: Minoru
authors.initials: M
authors.lastname: Nishihara
authors.forename: Norihiko
authors.initials: N
authors.lastname: Okushima
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Toda
authors.forename: Masaya
authors.initials: M
authors.lastname: Kiyuna
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001706:Biopsy; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D002272:Carcinoembryonic Antigen / Q000097:blood; D003110:Colonic Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*; D004338:Drug Combinations; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D010094:Oxonic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D016879:Salvage Therapy; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
chemical_list: D002272:Carcinoembryonic Antigen; D004338:Drug Combinations; D009944:Organoplatinum Compounds; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin